Across TCGA pan-cancer cohorts, MUC21 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MUC21 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MUC21 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MUC21 expression acts as an unfavorable survival marker.

HNSC and LUAD are the cancer types where MUC21 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.935	1.000	.008	10	view →
LUAD	DFS	Median	All	0.403	1.000	.003	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: MUC21 tumor-vs-normal RNA expression · all MUC21 data types